BACKGROUND: Rowell syndrome is a rare disease characterized by a combination of lupus erythematosus (LE) and erythema multiforme (EM)-like lesions and a characteristic immunologic pattern, including speckled pattern of antinuclear antibody (ANA), positive anti-Ro/SSA or anti-La/SSB, and positive rheumatoid factor (RF). This disease was first described in 1963, and to date, about 95 cases of EM-like lesions associated with LE have been described in the literature, with the majority of cases being reported in adult female patients. Here, we describe the case of a 17-year-old male patient exhibiting both systemic LE and EM lesions together with ANA and anti-Ro/SSA positivity who was successfully treated with systemic corticosteroids and hydroxychloroquine.
Rowell Syndrome: A Diagnostic Challenge / Gallo, Lucia; Megna, Matteo; Festa, Bianca; Stellato, Pio; DI PINTO, Rosita; Fabbrocini, Gabriella; Ferrillo, Maria. - In: THE JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY. - ISSN 1941-2789. - 13:4(2020), pp. 40-42.
Rowell Syndrome: A Diagnostic Challenge
Lucia Gallo;Matteo Megna;Bianca Festa;Pio Stellato;Rosita di Pinto;Gabriella Fabbrocini;Maria Ferrillo
2020
Abstract
BACKGROUND: Rowell syndrome is a rare disease characterized by a combination of lupus erythematosus (LE) and erythema multiforme (EM)-like lesions and a characteristic immunologic pattern, including speckled pattern of antinuclear antibody (ANA), positive anti-Ro/SSA or anti-La/SSB, and positive rheumatoid factor (RF). This disease was first described in 1963, and to date, about 95 cases of EM-like lesions associated with LE have been described in the literature, with the majority of cases being reported in adult female patients. Here, we describe the case of a 17-year-old male patient exhibiting both systemic LE and EM lesions together with ANA and anti-Ro/SSA positivity who was successfully treated with systemic corticosteroids and hydroxychloroquine.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.